Meeting report: 4th ISIRV antiviral group conference: Novel antiviral
therapies for influenza and other respiratory viruses by McKimm-Breschkin, Jennifer L. & Fry, Alicia M.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Public Health Resources Public Health Resources
2016
Meeting report: 4th ISIRV antiviral group
conference: Novel antiviral therapies for influenza
and other respiratory viruses
Jennifer L. McKimm-Breschkin
CSIRO, 343 Royal Parade, Parkville, Australia, mck245@csiro.au
Alicia M. Fry
Centers for Disease Control and Prevention, agf1@cdc.gov
Follow this and additional works at: http://digitalcommons.unl.edu/publichealthresources
This Article is brought to you for free and open access by the Public Health Resources at DigitalCommons@University of Nebraska - Lincoln. It has
been accepted for inclusion in Public Health Resources by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
McKimm-Breschkin, Jennifer L. and Fry, Alicia M., "Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies
for influenza and other respiratory viruses" (2016). Public Health Resources. 444.
http://digitalcommons.unl.edu/publichealthresources/444
Meeting report
Meeting report: 4th ISIRV antiviral group conference: Novel antiviral
therapies for influenza and other respiratory viruses
Jennifer L. McKimm-Breschkin a, *, Alicia M. Fry b
a CSIRO, 343 Royal Parade, Parkville, Australia
b Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA
a r t i c l e i n f o
Article history:
Received 21 January 2016
Accepted 22 January 2016
Available online 9 February 2016
Keywords:
Respiratory virus
Isirv-AVG
Antiviral
Influenza
a b s t r a c t
The International Society for Influenza and other Respiratory Virus Diseases (isirv) held its 4th Antiviral
Group Conference at the University of Texas on 2e4 June, 2015. With emerging resistance to the drugs
currently licensed for treatment and prophylaxis of influenza viruses, primarily the neuraminidase in-
hibitor oseltamivir phosphate (Tamiflu) and the M2 inhibitors amantadine and rimantadine, and the lack
of effective interventions against other respiratory viruses, the 3-day programme focused on the dis-
covery and development of inhibitors of several virus targets and key host cell factors involved in virus
replication or mediating the inflammatory response. Virus targets included the influenza haemag-
glutinin, neuraminidase and M2 proteins, and both the respiratory syncytial virus and influenza poly-
merases and nucleoproteins. Therapies for rhinoviruses and MERS and SARS coronaviruses were also
discussed. With the emerging development of monoclonal antibodies as therapeutics, the potential
implications of antibody-dependent enhancement of disease were also addressed. Topics covered all
aspects from structural and molecular biology to preclinical and clinical studies. The importance of
suitable clinical trial endpoints and regulatory issues were also discussed from the perspectives of both
industry and government. This meeting summary provides an overview, not only for the conference
participants, but also for those interested in the current status of antivirals for respiratory viruses.
© 2016 Elsevier B.V. All rights reserved.
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1. Background
The International Society for Influenza and other Respiratory
Virus Diseases (isirv) is an independent, international scientific
professional society promoting the prevention, detection, treat-
ment, and control of influenza and other respiratory virus dis-
eases. The isirv Antiviral Group (isirv-AVG) was established
following the merger in April 2011 of the former Neuraminidase
Inhibitor Susceptibility Network (NISN) with isirv. The Group aims
to promote understanding of the means of prevention, treatment
and control of influenza and other respiratory virus diseases,
including the emergence of antiviral resistance. To communicate
preclinical and clinical developments of potential novel/new an-
tivirals three meetings have been held annually in different re-
gions of the world.
The 4th isirv Antiviral Group Conference was held at the
University of Texas on 2e4 June, 2015. With emerging resistance
to the drugs currently licensed for treatment and prophylaxis
of influenza (primarily the neuraminidase inhibitor (NAI) osel-
tamivir phosphate (Tamiflu) and the M2 inhibitors amantadine
and rimantadine) and the lack of effective interventions against
other respiratory viruses, the 3-day programme focused on the
discovery and development of inhibitors of several virus targets
and key host cell factors involved in virus replication or in
mediating the inflammatory response. Virus targets included the
influenza haemagglutinin, neuraminidase and M2 proteins, and
both the respiratory syncytial virus (RSV) and influenza poly-
merases and nucleoproteins. Therapies for rhinoviruses and
Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV).
and severe acute respiratory syndrome coronaviruses (SARS-CoV)
were also discussed. With the emerging development of mono-
clonal antibodies as therapeutics, the potential implications of
antibody-dependent enhancement of disease were also
addressed. Topics covered all aspects from structural and mo-
lecular biology to preclinical and clinical studies. The importance
of suitable clinical trial endpoints and regulatory issues were also
discussed from the perspectives of both industry and govern-
ment. This meeting summary provides an overview, not only for
the conference participants, but also for those interested in the
current status of antivirals for respiratory viruses.
2. Keynote lectures
2.1. Public health impact of antiviral therapy for respiratory
diseases
Nancy Cox, Centers for Disease Control and Prevention, Atlanta,
USA.
Prior to licensing of the NAIs in 1999, the aminoadamantanes
were the only drugs used for the treatment and prevention of
influenza. These target the virus M2 ion channel protein,
involved in virus uncoating in the endosome (see 9.3 below).
However, due to central nervous system complications in the
elderly and lack of efficacy against influenza B, they were not
widely employed. Additionally, since 2000 many viruses have
acquired mutations in the M2 gene conferring resistance,
including the current human A(H3N2) and A(H1N1)pdm09 vi-
ruses, and avian influenza A(H5N1) and A(H7N9) viruses which
have caused sporadic human infections. Resistance initially
emerged in China, possibly related to the ready availability of the
aminoadamantanes in over the counter medications, and use in
poultry feed.
The NAIs Tamiflu (prodrug oseltamivir phosphate), taken orally
as a capsule, and Relenza (zanamivir), an inhaled powder, were
approved in 1999e2000. More recently, peramivir (Rapivab),
administered intravenously, as well as a long-acting derivative of
zanamivir, laninamivir (Inavir), have been approved in some
countries. The US CDC recommends the use of NAIs for patients
with suspected or confirmed influenza who are hospitalised or at
high risk for complications due to influenza, including patients less
than 2 and more than 65 years of age, those with underlying
medical conditions or compromised immunity, and pregnant
women (CDC, 2015b). Clinicians are advised to use clinical judge-
ment to guide NAI treatment of outpatients who are not at high
risk. One study showed that antivirals are under-prescribed for
high-risk outpatients, with only 19% receiving a prescription when
presenting at less than 48 h post symptom onset (Havers et al.,
2014). Furthermore, only 7.5% of all laboratory-confirmed influ-
enza outpatients were given an antiviral prescription, versus 30%
who were prescribed antibiotics. With the recent emergence of the
novel influenza A(H5N2) circulating in poultry in the USA, CDC
recommends antiviral treatment as soon as possible for hospital-
ised patients with novel influenza A viruses associated with severe
infection.
While influenza vaccines are still recommended as the means of
primary protection (CDC, 2015a), in 2014 a new human H3N2 strain
emerged which was antigenically distinct from the H3N2 vaccine
component. Interim vaccine effectiveness against H3N2 virus in-
fections was estimated at only 23% in January 2015 (Flannery et al.,
2015). This new H3N2 virus resulted in the highest numbers of
H3N2 hospitalizations in the USA since records began more than 10
years ago. Thus the CDC focused communications on reminding
clinicians about recommendations for NAI use, regardless of
vaccination status.
Recently there has been controversy over the efficacy of the
NAIs. The Cochrane group carried out meta-analysis of clinical data
from 20 oseltamivir and 26 zanamivir trials (all enrolled out-
patients with uncomplicated influenza), concluding that oselta-
mivir provided a 17 h benefit for adults and a 29 h benefit for
children, and zanamivir, a 0.6 day benefit among all enrolled
participants, regardless of influenza infection (intention to treat
(ITT) population) (Jefferson et al., 2014). They failed to find a sig-
nificant decrease in the number of hospitalizations after treat-
ment, and concluded that, with the increased risk of nausea from
oseltamivir (4%) and possible psychosis, the harm from treatment
outweighed the benefits. However, the PRIDE study (Muthuri
et al., 2014), using meta-analysis of global hospitalizations of
more than 29,000 individual patients in 78 observational studies
from 2009 to 2010, showed that NAI treatment led to a 19%
decrease in mortality in adults, and, with early treatment, to a 50%
reduction in mortality. No significant benefit was observed in
children.
More recently, the Multi Party Group for Advice on Science
(MUGAS) repeated a meta-analysis of randomised, placebo-
controlled clinical trials of oseltamivir enrolling outpatient
adults using individual level patient data. They demonstrated a 1
day decrease in the time to alleviation of symptoms, a 44%
reduction in antibiotic prescriptions and a 60% decrease in hos-
pitalizations in the ITT influenza-infected population (Dobson
et al., 2015).
New antivirals are needed, but they face higher benchmarks
to prove efficacy, including demonstration of reduction of
severe complications due to influenza, and a recent mistrust of
studies funded by industry. This will lead to higher costs of
clinical trials and ultimately of the drugs. The dilemma is who
will pay?
2.2. Clinical development of antivirals for respiratory diseases
Fred Hayden, University of Virginia, USA.
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Recent clinical trials were disappointing for both the inhaled
long-acting derivative of zanamivir, laninamivir, in uncomplicated
influenza and intravenous peramivir in hospitalised patients, both
failing to meet the primary clinical endpoint of alleviation of
symptoms or normalization of vital signs. Additionally, DAS181, a
sialidase fusion protein, which acts by removing potential sialic
acid receptors for influenza (Belser et al., 2007), showed some
decrease in virus load in uncomplicated influenza, but no signifi-
cant clinical benefit (Moss et al., 2012). Combination therapy,
mostly of NAIs with other drugs against different targets (Hayden,
2013), are currently under evaluation, to try to increase potency
and reduce the likelihood of oseltamivir resistance. DAS181 is also
being tested against parainfluenza (PIV) viruses, which also use
sialic acid receptors (Jones et al., 2013).
For rhinoviruses, pleconaril, a capsid binding inhibitor, resulted
in some decrease in total symptom severity, but it was not broadly
effective against the multiple different strains of the virus. A newer
derivative, vapendivir, is being tested in adults with rhinovirus
infections and asthma (ClinicalTrials.gov, 2015). Many other in-
hibitors were discussed in more detail in the subsequent program.
3. Inhibitors of virus polymerases, nucleoproteins and
accessory proteins
3.1. Influenza
3.1.1. Keynote lecture: structure, mechanism and drug targeting of
influenza polymerase
Stephen Cusack, EMBL, Grenoble, France.
Influenza RNA-dependent RNA polymerase is a good drug target
since its active site is highly conserved. The polymerase complex,
composed of three proteins, PA, PB1 and PB2, is essential for tran-
scription, to generate capped viral mRNAs, replication, to generate
the full length vRNA genome for incorporation into new virions,
and antigenome cRNA, providing the template for full length vRNA.
PB2 binds host cell pre-mRNA associated with the cell Pol II, then
short 50 capped RNA fragments are cleaved off by the PA endonu-
clease, in a process known as cap snatching. Transcription elon-
gation is then initiated by PB1 using the capped primer. Early
attempts at crystallization of soluble fragments had limited success.
However more recently, expression of the complete trimeric
polymerases, using self-cleavable polyproteins, of the novel bat
influenza virus H17N10 and influenza B enabled solving the X-ray
crystal structures in complex with the RNA promoter, comprising
16e18 nucleotides from the 30 and 50 ends of vRNA, to between 2.7
and 3.4 Å resolution (Pflug et al., 2014; Reich et al., 2014). The
structures suggest that the cap-binding domain of PB2 rotates by
70, first allowing the endonuclease to cleave the host pre-mRNA,
to an alternative configuration in which the capped oligomer can
enter the polymerase active site and prime transcription. All three
subunits are thus involved in RNA binding and transcription. When
the influenza B polymerase was complexed with 50 vRNA only, it
yielded a different structure to that of the complex with both the 30
and 50vRNAs, which may represent an alternative conformation
active in cap snatching.
The La Crosse bunyavirus which has only 3 RNA segments has a
single L polymerase protein. This is similar in total size to the
influenza complex, and structural analysis showed it to have similar
overall architecture and domain structure as the influenza enzyme,
despite their divergence (Gerlach et al., 2015).
Structure-guided drug design has been used to develop in-
hibitors against the cap snatching PB2 subunit and the PA endo-
nuclease (Kowalinski et al., 2012; Pautus et al., 2013). The PA
inhibitor chelates the two critical manganese ions in the active site
of the enzyme. Savira (an ESRF spin off) and Roche are undertaking
further development of the polymerase inhibitors. Resistance
studies in vitro have shown that after 10 passages of A/Aichi/2/68
(H3N2) virus in the presence of an endonuclease inhibitor there
was no change in the IC50.
3.1.2. Safety and efficacy of JNJ-63623872 (VX-787)
Lorant Leopold, Janssen Pharma, Titusville, USA.
JNJ-63623872 (VX-787) is a non-nucleoside inhibitor targeting
PB2 (Byrn et al., 2015; Clark et al., 2014). It inhibits production of
viral mRNA, preventing death of infected cells, unlike the NAIs
which still allow cell death. It was effective against all influenza A
strains tested in cell culture, including those which are resistant to
NAIs, and was also effective in reducingmortality in both H1N1 and
H5N1 lethal mouse models. At 3 mg/kg it resulted in up to 50%
decrease in mortality due to A/Puerto Rico/8/34 (PR8, H1N1)
infection in mice. With 10 mg/kg it could be delivered up to 120 h
post-infection and still lead to an 80% decrease in mortality. Syn-
ergy was demonstrated in combinationwith oseltamivir, zanamivir
or favipiravir in vitro. While 0.3 mg/kg alone was not protective in
mice, there was a synergistic effect with oseltamivir leading to
100% survival.
In a human challenge study different doses were tested,
including 100 or 400 mg once daily for 5 days, or a loading dose of
900 or 1200mg on the first day followed by 600mg once daily for 4
days. The primary endpoint was the area under the curve for virus
shedding, determined by virus infectivity in cell culture and qRT-
PCR. A statistically significant decrease in virus shedding was
seen in the 1200/600 cohort, although the duration of virus shed-
ding was not affected. Therewas also a dose-dependent decrease in
symptom scores and duration of symptoms. Resistance screening
revealed a mutation M431I in the PB2 gene in four of 72 patients,
which resulted in a 57-fold reduction in sensitivity. However,
mutant viruses had reduced fitness, estimated to be 8% of wild type.
Cusack commented that resistance was seen within 2 passages
in vitro. Mutation of phenylalanine 323, involved in tight binding of
the inhibitor to influenza A, to serine leads to resistance. Lack of this
phenylalanine in influenza B PB2 accounts in part for naturally poor
binding and lack of activity against influenza B. A phase 2b trial is
evaluating the dose range and once versus twice daily dosing in
healthy patients.
3.1.3. The nucleoprotein of influenza virus, a target for new
antivirals
Anny Slama-Schwok, INRA, Jouy en Josas, France.
Influenza ribonucleoprotein (RNP) complexes are composed of
the three subunits of the polymerase associated with the viral RNA
genome covered by multiple copies of the nucleoprotein (NP). The
NP is a highly conserved protein and thus potentially a good target
for a broadly-reactive antiviral. The recent structures of the poly-
merase complex and cryo-electron microscopy studies of the RNP
have provided the basis for in silico screening of the Sigma cata-
logue for inhibitors of NP-polymerase and NP-RNA interactions.
Naproxen, a known anti-inflammatory inhibiting cellular cylcoox-
ygenase 2 (COX-2), was identified as a competitor of NPeRNA
interaction, and protected the NP C-terminus against proteolysis.
Naproxen reduced infection of both H3N2 and H1N1 viruses in cells
with an EC50 of 50 mM, and at 2e8 mg/kg per day decreased virus
titers in mice (Lejal et al., 2013). Two derivatives were synthesised
to be more specific for viral RNP, naproxen A and CO (Tarus et al.,
2015). Naproxen CO competes with RNA binding to NP and de-
stabilizes NP-RNA oligomers while stabilizing monomeric NP. It
was more potent with an IC50 of 2e3 mM, more soluble and less
toxic than naproxen, but no longer inhibited COX-2 in human
A549 cells.
Work on anti-inflammatory compounds targeting the NADPH
J.L. McKimm-Breschkin, A.M. Fry / Antiviral Research 129 (2016) 21e3824
oxidase (NOX) are aimed at a dual antiviral and anti-inflammatory
approach.
3.1.4. Identification and characterization of influenza variants
resistant to a viral endonuclease inhibitor, L-742,001
Gyanendra Kumar, St Jude Children's Research Hospital, Mem-
phis, USA.
L-742,001 is a diketo acid inhibitor of the influenza virus poly-
merase PA subunit (Stevaert et al., 2015). Stevaert et al. (2013)
previously described mutations which confer reduced sensitivity
(Stevaert et al., 2013). Kumar carried out random mutagenesis as
natural mutants did not emerge after 10 passages in cell culture.
They generated a plasmid library, then used reverse genetics to
generate recombinant PR8 viruses. Thesewere then passaged in the
inhibitor for 3e4 passages, and then potentially resistant viruses
were selected. Mutations included I79L, E119D, T20A (also seen by
Stevaert et al., 2013), and F105S. Mutations marginally reduced
polymerase activity, but viruses did not appear to lose fitness, with
similar growth properties in vitro and similar weight loss, virus
titers and MLD50 in mice.
3.1.5. Structure-based development of a new class of influenza
endonuclease inhibitors
Joseph Baumann, Rutgers University, USA.
Crystals of an N-terminal domain of the endonuclease (PA) of an
A(H1N1)pdm09 virus were used for fragment screening to identify
new chemical entities binding to the enzyme active site. A 3-
hydroxy-2-pyridone scaffold was shown to bind at 3 sites, identi-
fying a newmode of chelation of the active site metal ions (Bauman
et al., 2013). A third Mnþþ ion, not previously identified, was also
detected. SAR studies led to improved binding, reducing the IC50
from 16 mM to 11 nM in a fluorescence based enzyme assay, and
11 mM in a plaque reduction assay (PRA) against PR8 (H1N1). The
IC50s in enzyme assay varied depending onwhether Mgþþ or Mnþþ
was in the reaction. The most active compounds had an IC50 of
0.2 mM in the PRA.
3.1.6. Clinical and anti-influenza virus effects of favipiravir, a novel
anti-RNA virus, anti-influenza agent
Carol Epstein, Medivector Inc, Boston, USA.
Favipiravir, T-705, is a selective inhibitor of the RNA-dependent
RNA polymerase of influenza virus, and is also reported to inhibit a
broad range of other RNA viruses (Furuta et al., 2013; Oestereich
et al., 2014). Additionally, since it does not target the NA, it is
effective against oseltamivir-resistant viruses (Tarbet et al., 2014).
Over 1500 patients have been studied in clinical trials, evaluating
symptom improvement and emergence of resistance. In the first
phase 2 trial of 550 patients over 5 seasons, no significant benefit
was observed. The second phase 2 trial evaluated twice (BID) versus
three times (TID) daily administration with different dosing:
1200 mg TID for 1 day, then 600 mg TID for 4 days; a 2400 mg
loading dose and two 600 mg doses on day 1, followed by 600 mg
TID for 4 days; or 1800 BID on day 1 and 800 mg BID on days 2e5.
The higher loading dose was needed to maintain the Cmin levels of
20 mg/ml. The BID and TID groups both showed a more rapid
decrease in virus titers compared to the placebo groups. Interest-
ingly, the BID group showed a statistically significant decrease in
the time to resolution of symptoms, but the TID did not. Among
individual symptoms, a statistically significant decrease was
demonstrated for 6 symptoms, but not for fever. No resistance has
been detected in more than 700 clinical samples tested so far, with
more than 1500 samples to test from a Phase 3 multi-country trial
that recently concluded enrolment.
3.2. Respiratory syncytial virus
3.2.1. Discovery and development of ALS-8176, a nucleoside
analogue inhibitor of the RSV RNA polymerase
Julian Symons, Alios Biopharma Inc, San Francisco, USA.
The RSV L protein is a viral RNA-dependent RNA polymerase
that contains multiple enzyme activities required for RSV replica-
tion. Using a cell based screening assay, ALS-8112, a novel cytidine-
based analogue, and its orally available prodrug, ALS-8176, were
identified as potent and specific inhibitors of the replication of
laboratory and clinical strains of RSV A and B (Deval et al., 2015),
with EC50s of approximately 100 nM and a Ki of 90 nM for the
enzyme. Both a 20F and the 40ClCH2 groups contributed to
the selectivity of ALS-8112. In vitro, the inhibitor caused chain
termination of viral RNA synthesis, but did not inhibit cellular or
unrelated virus RNA polymerases. It also inhibited related para-
myxoviruses, including human metapneumovirus and para-
influenza virus 3. High levels of the ALS-8112-triphosphate formed
in A549 and primary epithelial cells. Oral administration to non-
human primates resulted in high levels of the NTP in the lung,
with a half-life of 29 h.
In human challenge studies in adult volunteers (DeVincenzo
et al., 2015), ALS-8176 was administered either with a high
loading dose of 750 mg followed by a maintenance dose of 150 or
500 mg, or as a constant dose of 375 mg. In the placebo group, by
quantitative RT-PCR the peak RSV RNA titer was around 104 log10 at
3.5 days post challenge. In the 750/500 mg and 750/150 mg groups
there was an immediate decrease in the RSV RNA levels, and a
decrease in symptom scores and mucus weight. In the 375 mg
group there was an initial increase in virus RNA followed by a
decrease, thus indicating the importance of the high loading dose.
ALS-8176 was well tolerated and no resistant virus was isolated,
although in vitro after 35 passages mutations were found in the
active site of the L protein. It is currently undergoing evaluation in
hospitalised infants.
3.2.2. RSV polymerase and nucleoprotein inhibitors: mechanism of
action and resistance
Qin Yu, AstraZeneca R&D Boston, Waltham, USA.
AZ-27, a polymerase inhibitor (Tiong-Yip et al., 2014), was active
against both RSV A (average EC50 ¼ 24 ± 9 nM) and B (average
EC50¼ 1.0 ± 0.28 mM) subtypes in many cell lines, and was effective
when added up to 24 h post infection. There was no detectable
cytotoxicity at 100 mM. AZ-27 inhibits an early stage in mRNA
transcription, as well as genome replication, by inhibiting initiation
of RNA synthesis from the promoter (Noton et al., 2015). Resistant
viruses were isolated after 7 passages in culture; a dominant mu-
tation, Y1631H, in the putative capping enzyme domain of L protein,
resulted in a greater than 5000-fold increase in EC50 against AZ-27.
The RSV nucleoprotein (N) is essential for virus replication and
assembly as part of the viral RNP complex. Previously, RSV604, a
benzodiazepine, has been reported to inhibit both RSV RNA syn-
thesis and the infectivity of released virus, with an EC50 of
approximately 1 mM (Challa et al., 2015). Its potency is cell line
dependent. Yu and colleagues reported here that they have iden-
tified a novel thienodiazepine as an N inhibitor with improved
potency and broad spectrum activity against both RSV A and B
strains, although it was also cell type dependent. The compound
demonstrated direct binding to recombinant N fragments by sur-
face plasmon resonance (SPR) with a Kd of 1.93 mM. An X-ray
coecrystal structure showed the binding site overlapped the NeP
interaction site. Mutations at residues N80 and N28 caused reduced
inhibition, being resistant to 2x, but not to 10x, the EC50. They did
not, however, affect inhibitor binding to the N protein as assessed
by SPR, suggesting that the mechanism of ‘resistance’ may not be
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due to reduced inhibitoreN binding. The dual mechanism of action
for these N inhibitors highlights the potential for this class of in-
hibitor in delivering efficacy and suppressing resistance.
3.3. Influenza NS1
3.3.1. Novel broad spectrum antiviral against influenza blocks
dsRNA binding to NS1A protein and restores antiviral responses
Ji-Young Min, Institut Pasteur, Korea.
The influenza A virus non-structural 1 (NS1A) protein is a
known antagonist of the host antiviral response. A small molecule,
named BOC, inhibited human seasonal H1N1, H3N2, and B viruses
and avian H5 and H7 subtype viruses. The dsRNA binding pocket of
the NS1A protein was shown to be the putative target based on an
in vitro dsRNA binding assay. Influenza A virus-infected cells
showed increased NF-kB nuclear translocation and elevated levels
of various cytokines related to interferon-stimulated genes. BOC
administered to mice infected with an avian influenza virus
reduced lung virus titers in the early stage of infection. Results thus
suggest BOC may abrogate the antagonistic responses of the NS1A
protein.
4. New inhibitors of influenza NA and M2 activities
4.1. Neuraminidase
4.1.1. The influenza neuraminidase - old target, new approaches
Jenny McKimm-Breschkin, CSIRO, Parkville, Australia.
While the currentNAIs are based on the transition state analogue
DANA, a new series of compounds, based on the natural substrate
sialic acid, 2,3, difluoro sialic acids (DFSA), have recently been
described (Kim et al., 2013). DFSAs require the catalytic activity of
theNA to bind, hence are termedmechanism-based inhibitors. They
form a covalent link to a tyrosine in the enzyme active site. Unlike
the NAIs, they are not competitive inhibitors and their efficacy de-
pends on a slow turnover of the covalently linked inhibitor. Sub-
stitution on the sugar ring, with either 4-amino or 4-guanidino
groups, affected affinity and rates of binding and dissociation in an
IC50 kinetics assay (Barrett et al., 2011). Even more striking was the
effect of the orientation of the 3 fluoro group, with the equatorial
being more potent than the axial. DFSAs have broad efficacy, with
IC50s in enzyme assays and inplaque reduction assays in the lownM
to mM range, and can protect mice from a lethal influenza infection.
They are also effective against viruses resistant to oseltamivir and
zanamivir. Theoretically resistance toDFSAs shouldbemoredifficult
to select, since mutations would compromise the NA function. No
resistant viruses were selected after 12 passages of an A(H1N1)
pdm09and an influenzaB virus invitro,with virus reduced to almost
undetectable levels. A further 3 passages in a lower drug concen-
tration, however, led to isolation of a small plaque variant from the
A(H1N1)pdm09 virus, which was highly resistant in the plaque
reduction assay. The mutant virus had barely detectable enzyme
activity, but replicated to comparable titers in vitro as the wild type
virus. Preliminary results suggest a novel mutation/s in the NA,
which remains to be confirmed. These DFSAs are also active against
human PIV3 (Dirr et al., 2015; Streltsov et al., 2015). Since the NAs of
human H3N2 (Mohr et al., 2015) and H1N1 (Hooper et al., 2015)
viruses can demonstrate receptor binding as well as the catalytic
function, with a recent focus on antivirals targeting the HAwe need
to understand this secondary role of theNA,whichmaycompensate
for inhibition of the HA receptor binding function. We may need to
target both the HA and NA.
4.1.2. New inhibitors of influenza A neuraminidases
Mario Pinto, NSERC, Ottawa, Canada.
In addition to the catalytic site, in group 1 NAs amino acids
149e152 form a loop, which either projects into the active site in
the closed conformation, or remains outside the active site in the
open conformation, creating the 150 cavity (Adabala et al., 2013;
Amaro et al., 2011; Wang et al., 2011). Pinto and colleagues have
created a carbocyclic analogue of zanamivir, by replacing the hy-
drophilic glycerol side chainwith the hydrophobic pentyloxy group
of oseltamivir (Kerry et al., 2013; Mohan et al., 2014). This inhibitor
targets only the catalytic site, and showed nM potency in the NAI
assay (Ki ¼ 0.46 nM; Ki (zanamivir) ¼ 0.16 nM) and an EC50 of
80 nM in cell culture; activity was only 10-fold lower against the
H275Y oseltamivir resistant mutant (100e1000 fold resistant). This
appears to be due to increased flexibility of the pendant pentyloxy
group and the ability to pivot about a strong hydrogen-bonding
network. However, its properties suggest that it would still only
be suitable for topical application.
Pinto also described a series of triazole-containing carbocyles,
related to oseltamivir, which bound in both the catalytic site and
150 cavity (Adabala et al., 2013; Amaro et al., 2011; Mohan et al.,
2010; Wang et al., 2011). Inhibition of virus replication in vitro
with triazole derivatives containing either an amino or guanidino
modification indicated that the guanidinium compound had higher
efficacy against an N2 subtype, at a concentration of 20 mM, and did
not inhibit replication of an N1 subtype virus even at a concen-
tration of 100 mM. He also briefly described the serendipitous dis-
covery of a potent spirolactam NA inhibitor (Mohan et al., 2014).
4.1.3. Delayed oseltamivir and T-705 combination therapy protects
mice against lethal influenza A(H5N1) infection
Bindumadhav Marathe, St Jude Chidren's Research Hospital,
Memphis, USA.
Due to the emergence of resistance to oseltamivir, several
groups are investigating combinations of therapeutics directed
against different virus targets. Oseltamivir (20 mg/kg), T-705
(50 mg/kg) or a combination of the two was administered to mice
at 48, 72, 96 or 120 h post-infection. All mice were protected at 48
and 72 h, but at 96 h only the combination gave 100% protection.
After 120 h the single drugs had a 25% survival rate, compared to
80% with the combination. There was a 2 log10 decrease in mouse
lung virus titers for the monotherapy, and a 4 log10 decrease for the
combination therapy. Analysis of lung tissue by immunohisto-
chemistry and histomorphometry revealed that combination
therapy restricted virus spread and reduced the extent of lesions by
30% compared with monotherapy. Combination therapy also
reduced the pro-inflammatory cytokine response, which reduced
disease severity and facilitated recovery.
4.1.4. Influenza viral load and peramivir kinetics after a single
administration in children
Masaktoki Sato, Fukushima Medical University, Japan.
While peramivir (Rapivab) administered as a single dose (i.v.) has
been licensed in Japan for treatment of adults, children and infants,
it has only been approved in the USA for acute uncomplicated
influenza in patients 18 years and older. This study investigated the
pharmacokinetics of peramivir in children (Sato et al., 2015). While
themean serumperamivir concentration among28 children at 0.5 h
after a 10 mg/kg dose was 88.9 mM, after 1, 2, 3, 4 and 5 days it was
reduced to 83.2, 25.1, 17.1, 6.2 and 4.6 nM, respectively. The mean
concentration in the URT at 0.5 h after administration was 5.1 mM
and 48.3 nM at 1 day, but the drug was undetectable after day 2.
While viral RNA load in both H3N2 and H1N1 infections decreased
from day 0 to day 3, it increased in 9/12 patients after day 3. The
decrease in viral RNA load was much less for influenza B than
influenza A. No resistant virus was detected. Hence a single per-
amivir dose appears to be inadequate virologically, and
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readministration should be considered in severe cases.
4.2. Influenza M2
4.2.1. Is M2 a good target to combat drug resistance in the influenza
A viruses?
Jun Wang, University of Arizona, Tucson, USA.
Once the influenza virus binds to sialic acid receptors, it is taken
up into the endosome, where the low pH activates the formation of
the M2 ion channel, causing an influx of protons, into the virion
interior. This results in dissociation of the M1 matrix protein from
the virus RNP, which is then released into the cell. TheM2 protein is
highly conserved, and can be inhibited by the adamantanes.
However resistance arises rapidly, due to three major mutations,
L26F, V27A or S31N, S31N being the most common. The S31N
mutant has a more contracted channel compared with that of the
wild type (WT). It is hypothesised that the pore undergoes a
conformational change from open-closed to closed-open as the Hþ
goes from outside to inside. Guided by molecular dynamics simu-
lations, NMR and X-ray crystallography studies, the group devel-
oped amantadine derivatives which are effective against the
resistant mutants (Wang et al., 2015, 2013). One compound which
contains a charged ammonium group, M2WJ332, sits inside the
channel, and in the plaque reduction assay has an EC50 of 153 nM
against the S31N mutant in comparison to 328 nM for amantadine
against the WT M2. Four passages in drug concentrations
increasing from 300 to 600 nM did not select a resistant mutant.
However, greater increase in drug concentrations (330, 376 nM, 1.6
and 35.9 mM) selected resistant mutants with an L26I mutation, and
by passage 6 a reversion of the N31S occurred, which decreased
binding. However, the limitation remains that new compounds
need to bind both the wild type and mutant M2s, and the L26I
mutation is found naturally in avian viruses isolated from wild
birds. Additionally, the BM2 of influenza B viruses is not inhibited
by aminoadamantanes.
5. Inhibitors of virion attachment/fusion proteins
5.1. Influenza
The influenza virus HA protein is a homotrimer, in which each
monomer is composed of two disulfide-linked subunits, HA1 and
HA2. TheHAbinds to sialic acid receptors on the cell surface, and the
virus is then taken up into endosomes, where the low pH leads to a
conformational change in the HA trimer to its fusogenic form. HA1
forms the head region of the protein, which is primarily involved in
receptor binding, whereas HA2, referred to as the stem region, is
involved inpromoting virusehostmembrane fusion. Various groups
have targeted the HA to try to either stabilize the prefusion form or
block the receptor binding site. Antibodies directed against the head
region appear to bemore potent, whereas those directed to the stalk
region appear to be more broadly reactive.
5.1.1. The influenza HA as an antiviral target
George Gao, Chinese Academy of Sciences, Bejing, China.
Gao described the discovery of an anti-stem monoclonal anti-
body, CT149, which was isolated from convalescent plasma from
patients infected with the A(H1N1)pdm09 virus in 2009 (Wu et al.,
2015). CT149 neutralised all group 2 H3N2 viruses tested and two
H7N9 viruses, but surprisingly only some group 1 influenza viruses,
including 1/6 H1, two H5 and two H9N2, inhibiting low pH-induced
HA-mediated membrane fusion. Both the heavy and light chains
are involved in binding, and the antibody cross-links two mono-
mers of the trimer. This antibody protects against H3N2 infection
both in vitro and in mice.
A second antibody, MAb#14, derived from an H7N9 virus-
infected patient binds near the receptor binding site. It sits above
the 190 helix, interacting partly with the 130 and 150 loops in the
head of the HA. However it is specific only for the H7 HA, since this
region is not conserved.
5.1.2. Blocking influenza virus by stabilizing the pre-fusion
conformation of HA
Megan Shaw, Mount Sinai Hospital, New York, USA.
High throughput screening used a recombinant influenza A/
WSN/33 virus with the luciferase gene replacing the HA gene and
cells expressing the HA. Luminescence was only detected if whole
virus was produced. From almost 106 compounds, the hit rate was
0.5%, (4582), with 744 compounds showing a dose response effect
(White et al., 2015). The top five were screened against wild type
viruses, with three showing influenza A specific inhibition, but not
broadly reactive. The other two were broadly reactive, M4 reacting
against a subset of viruses andM53 showing reactivity against both
RNA and DNA viruses, suggesting a host cell target. The three
influenza-specific hits were S57, which had broader reactivity,
interacting with the C-terminus of the NP, S119, reacting with the
N-terminus of the NP protein, and S20, reacting with the HA of
group 1 viruses, but not H3N2 or influenza B viruses. When tested
against wild type virus, S20 had an IC50 of 80 nM and caused a
maximum reduction in virus titers of >3 log10 with low toxicity
(CC50 40 mM). Time of addition assays and use of an HA/NA pseu-
dotype HIV particle showed that S20 inhibited entry. Resistant vi-
ruses were selected after 4 passages in vitro, all with mutations
affecting the HA, primarily around the “B” loop structure con-
necting the large and small helices of the HA2 subunit (White et al.,
2015). In a red cell fusion assay, the pH of fusion (50% fusion at pH 5)
was lowered below pH 5 in the presence of S20, indicating stabi-
lisation of the prefusion form by S20. S20 also protected the HA
from conversion to the trypsin sensitive form under low pH con-
ditions. In contrast, the pH of fusion of a M59I mutant was unaf-
fected by S20. In silico docking studies predicted that S20 binds
both the HA1 and HA2 in the stalk region, corresponding to the area
where resistance mutations occurred.
5.1.3. Prophylactic and therapeutic protection against influenza by
a computationally engineered protein
Merika Treants, University of Washington, Seattle, USA.
A computationally designed and engineered small protein
HB36.6 (90 amino acids) protected mice against weight loss and
death when administered either as a single prophylactic dose 48 h
prior to virus challenge, or from 24 h post-infection when admin-
istered daily at 3 mg/kg. A synergistic response providing full
protectionwas seenwith suboptimal doses of oseltamivir (5mg/kg)
and HB36.6. To determinewhether an immune response developed
to the protein mice were immunised with multiple doses and were
then challenged with virus. No immune response to HB36.6 was
seen as mice were fully protected. IL-6, IL-10, IFN-g and IL-12 p7 all
of which increased in control mice, were all lower in the HB36.6-
treated mice, correlating with lower virus titers and more rapid
recovery. HB36.6 also reduced clinical signs in influenza-infected
ferrets. After intravenous administration HB36.6 could not be
detected in blood, hence pharmacokinetic studies are using inhaled
administration. Labelled compound appears to coat the respiratory
tract.
5.1.4. Novel family of peptides with potent antiviral activity against
influenza viruses
Seema Jasim, The Roslin Institute & Royal (Dick) School of Vet-
erinary Studies, University of Edinburgh, UK.
Approaches to novel antiviral compounds include the
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developmentof synthetic peptides that disrupt theentryof virus into
cells. Twopeptides, “FluPep” (a family of short, hydrophobic peptides
related to suppressors of cytokine signalling-1, SOCS, proteins)
and “Entry Blocker” (derived from the signal sequence of
fibroblast growth factor-4) were shown to have antiviral activity
against a panel of viruses in vitro and in vivo (Nicol et al., 2012). In
plaque reduction assays the FluPep was more effective against H1
than H3 or H4, although PR8 had lower sensitivity compared to the
A(H1N1)pdm09 virus. IC50s ranged from the low nM to ~100 nM
(Nicol et al., 2012). In PR8 recombinants with different HAs, sensi-
tivity was dependent on the HA. The Entry Blocker did not show the
same strain specificity. They acted upstream of the nuclear import of
the RNPs. The peptides caused aggregation of fluorescently labelled
virus particles on the surface of host cells, and appeared to slow
internalisation.Givenprophylactically inmice therewasadecrease in
virus titer, and some protection against weight loss.
5.2. Respiratory syncytial virus
5.2.1. Discovery and proof of concept of GS-5806 in RSV disease
Seth Toback and Mike Perron, Gilead, Foster City, USA.
GS-5806 is an orally available RSV inhibitor that targets the
fusion protein, blocking virus envelope fusion with the host cell
membrane (DeVincenzo et al., 2014; Mackman et al., 2015). It is
highly effective against both RSV A and B with a mean EC50 of
0.43 nM against 75 clinical isolates, (RSV A 0.51 nM and B 0.35 nM),
and low toxicity (SI > 23,000-fold). GS-5086 does not block RSV
attachment to cells, but interferes with virus entry, and cellecell
fusion. In a cell-based fusion inhibition assay the EC50 was ~2 nM.
Resistant viruses were isolated after 9 passages in vitro, with mu-
tations in the F protein, including L138F or F140L/N517I in RSV A,
conferring more than 2000-fold resistance, and F488L or F488S in
RSV B. These were cross-resistant to another RSV fusion inhibitor
VP-14637 (Douglas et al., 2005; McKimm-Breschkin, 2000), also
undergoing clinical development as an inhaled product (MDT-637).
In cotton rats a single IP dose of 0.3, 3 or 30 mg/kg GS-5806 was
administered 1 h prior to intranasal challenge with RSV. A 1.8 log10
difference was seen in virus RNA load in nasal wash and lung lavage
samples on day 4, in the 30 mg/kg group. In a small trial with 4
calves infected with 105 pfu of nebulised bovine RSV, and treated
1 h prior to infection and twice daily for 7 days with 2 mg/kg, there
was a non-significant 3-fold decrease in virus titer, but a significant
3-fold decrease in the symptom score.
A double blind placebo-controlled trial of GS-5806 was carried
out in healthy subjects experimentally infected with 104 pfu of the
RSV Memphis-37b strain. Nasal wash samples from day 2 were
tested for RSV by RT-PCR, and when positive or at day 5, whichever
was sooner, subjects were randomised into 7 cohorts, with ~20 in
each, and treated as follows: Cohorts 1e4 (day 1 50 mg; days 2e5
25 mg daily), Cohort 5 (day 1 50 mg; days 2e3 25 mg daily), Cohort
6 (day 1100 mg), Cohort 7 (day 1 10 mg; days 2e5 5 mg daily). All
patients in treatment groups 1e4 showed a significant decrease in
the area under the curve (AUC) for log10 virus load, (250.7 vs 757.7
log10 pfu equivalents), lowermucusweight (during 5 days after first
dose 6.9 vs 15.1 g, p ¼ 0.03), and lower symptom scores. Cohorts
5e7 had comparable results, although Cohort 7 did not show a
decrease in mucus weight. Resistance frequency was 5%, with
mutations the same as selected in vitro, but the viruses showed
decreased fitness. Plans are to test a higher single dose, >100mg, to
try to avoid resistance.
5.2.2. RSV antivirals: fusion inhibitors and beyond
John DeVincenzo, University of Tennessee, Memphis, USA.
John gave an overview of clinical observations and correlates of
protection. A higher virus load in the nose corresponds with more
severe disease and faster virus clearance correlates with faster
clinical improvement. Detection of virus mRNA by RT-PCR corre-
lates with virus RNA and is more sensitive than virus culture, with
RNA detected often to day 13, although generally cultures are
negative after day 6 (IgA in the sample may inhibit virus growth).
Lung pathology shows high virus staining, and low numbers of
immune cells. Unlike influenza where virus peaks at days 2e3 and
symptoms at days 3e4, for RSV virus load and symptoms peak at
the same time. Children have higher virus titers and shed virus for
longer compared to adults. Palivizumab/Motavizumab monoclonal
anti-fusion antibodies, which are effective prophylactically
(AAPCID, 2014) showed no clinical efficacy for treatment of children
hospitalised with RSV (Ramilo et al., 2014).
A different approach to those already discussed is the use of
RNAi, for example, ALN-RSV01 targeting the N gene (DeVincenzo
et al., 2010). A trial using a nasal spray of ALN-RSV01, adminis-
tered daily for 2 days before and 3 days after RSV inoculation,
showed antiviral activity against RSV infection, with the proportion
of culture-defined RSV infections 71.4 and 44.2% in placebo and in
ALN-RSV01 recipients, respectively.
6. Inhibitors of seasonal and emerging threats
6.1. Antiviral strategies for prevention and treatment of rhinovirus
infections
Ronald Turner, University of Virginia, USA.
There are currently no antiviral agents licensed for the treat-
ment of rhinovirus infections. The common cold, generally a self-
limiting disease, was an original target, but no broadly effective
inhibitor has been demonstrated; additionally, it would need to be
cheap with no side effects. Interferon, protease inhibitors, and
capsid binding inhibitors all showed efficacy in laboratory models,
but not in patients (Hayden, 2013). Although rhinovirus (RV) is an
important cause of exacerbations of COPD and asthma, hence being
alternative targets, there is no good clinical model for evaluation of
therapies. Prophylaxis may be more feasible. In a family study there
was a significant decrease in asthma scores with pleconaril pro-
phylaxis. However, approaches to therapy have been further
complicated by the discovery of a new species of rhinovirus, RV-C,
in 2006, in addition to the known RV-A and RV-B viruses
(Palmenberg and Gern, 2015). As with RV-B they are inherently
resistant to capsid binders and have a different cellular receptor to
both RV-A and RV-B (CDHR3 instead of ICAM-1). Host-directed
therapies, such as TLR antagonists and probiotics, may be prom-
ising, and recent studies have reported some beneficial effect of
probiotics (Lactobacillus spp.) on the occurrence of common cold
illnesses in children (Ballengee and Turner, 2014).
6.2. Severe illness associated with EV-D68 infection in the United
States and approaches to management
Sue Gerber, Centers for Disease Control and Prevention, Atlanta,
USA.
Enterovirus EV-D68 was first identified in 1962. Unlike other
enteroviruses, which can cause febrile rashes and neurological
syndromes, EV-D68 is commonly associated with respiratory illness
and may play a role in asthma exacerbation. In the summer and fall
of 2014 there was a large increase in severe respiratory illness in the
USA and the CDC and state health laboratories identified 1,529
people PCR positive for EV-D68 (Midgley et al., 2015); however
rhinovirus, Coxsackie virus and echoviruses will also be detected by
the rhinovirus/enterovirus multiplex PCR. Using VP1 sequencing to
identify EV-D68, 46% of specimenswere positive for EV-D68. Several
cases of flaccid myelitis have been temporally related to EV-D68
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infection but a causal role of EV-D68 has not been established. A new
real-time RT-PCR test is available from the CDC (Zhuge et al., 2015).
Three strains have been identified with 92% belonging to one strain,
7.4% to the second, and a single case of the third strain. The virus
grows in MK cells and human lung A549 cells and binds to a2,6
linked sialic acids. It is sensitive to pleconaril and other capsid
binding inhibitors in vitro, and a randomised double blind placebo
controlled trial suggested a shorter time to culture and PCR negative
status with oral pleconaril. DAS181 which removes sialic acid re-
ceptors is also being evaluated (Abzug et al., 2015).
6.3. New targets and approaches for coronavirus antiviral
inhibitors
Mark Denison, Vanderbilt University, Nashville, USA.
Coronaviruses (CoVs) are endemic respiratory pathogens,
causing mainly colds, bronchiolitis and pneumonia. Additionally,
zoonotic transmissions have occurred, with the SARS-CoV and
more recently MERS-CoV. A large number of endogenous bat CoVs
have been identified. They have the largest genome of any RNA
virus, 26e32 kB, with up to three proteases, and a proof reading
exonuclease (nsp14-ExoN), endonuclease and helicase-ATPase. The
SARS ExoN-minus virus appears to acquire more lethal mutations
with 5-fluoro uracil mutagen treatment than the wild type (Smith
et al., 2013). It is also attenuated in mice. Hence high replication
fidelity is critical for CoVs. Treatment in vitro with ribonucleoside
analogues EV524 and EV1081 (Gilead) caused a 5 log10 reduction in
virus titer compared to the control. A combination of fidelity in-
hibitors and nucleoside analogues may provide broad activity
against multiple CoVs.
6.4. Functional dipeptidyl peptidase (DPP4) in mink supports entry
and replication of Middle Eastern Respiratory Syndrome
Coronavirus: American mink (Neovision vision), a novel in vivo
model of MERS-CoV infection
Thomas Voss, SRI International, Harrisonburg, Virginia, USA.
Dipeptidyl peptidase 4 (DPP4/CD26) is the receptor for MERS-
CoV. It is a multifunctional protein and is a target for diabetic
therapy, and apoptosis. A cell line derived from mink lung epithe-
lium is susceptible to infection by MERS-CoV. Although ferret cells
express DPP4, based on antibody reactivity, ferrets cannot be
infected. Mink challenged with MERS-CoV showed no signs of
illness or virus in any tissue. Different challenge routes were tried,
intranasal, oral, intratracheal and intraocular, and challenge doses
from 106 -109, and different challenge strains, including one
adapted to mink lung cells. As an alternative animal model, while
normal mice are not susceptible to MERS-CoV, expression of the
human DPP4 (hDPP4) overcomes the lack of susceptibility. The
transgenic hDPP4 mice develop severe and lethal respiratory dis-
ease upon inoculation with MERS-CoV and are potentially a suit-
able animal model for efficacy testing of therapeutic and
prophylactic countermeasures (van Doremalen andMunster, 2015).
6.5. Phase III multi-center clinical trial of nitazoxanide in adult
patients with uncomplicated influenza A and B and other influenza-
like illness: results on 1876 subjects from the United States, Canada,
Australia and New Zealand
Jean-Francois Rossignol, Romark Laboratories, Florida, USA.
Nitazoxanide has been approved for treatment of diarrhoea
associated with Giardia and Cryptosporidium infections. It has been
used in more than 75 million patients in the USA and Latin America
alone, hence has a known safety profile. It is an orally available,
small MW drug, with what appears to be broad antiviral activity,
including against influenza, PIV and RSV. Nitazoxanide appears to
block the maturation of the influenza virus HA (Rossignol, 2014). In
a phase 2b/3 trial in 2010e11, comparing 300 mge600 mg twice
daily in 624 patients, only treatment with 600 mg twice daily for 5
days was associated with a reduction in the duration of symptoms,
and a 1 log10 decrease in virus titer, in recipients with acute un-
complicated influenza (Haffizulla et al., 2014). Nitazoxanide has
also shown synergistic effects in vitro with NAIs (Belardo et al.,
2015). In a current Phase III trial, 600 mg of nitazoxanide is being
compared to nitazoxanide plus oseltamivir, oseltamivir, or placebo.
7. Monoclonal antibodies as therapeutics
7.1. Monoclonal antibodies as therapeutics against respiratory
viruses
Wayne Marasco, Harvard Medical School, Boston, USA.
In studies of respiratory viruses, this group has used non-
immune human antibody phage display libraries as a source of
human monoclonal antibodies (mAbs). As a complementary strat-
egy, they have used single memory B cell cloning to isolate broadly
neutralizing antibodies. To isolate antibodies against the SARS-CoV
and MERS-CoV blood samples were obtained from China and Ara-
bia. Binders were identified using pseudotyped viruses. An initial
SARS-CoV mAb, 80R, which neutralised all 2002e3 isolates, in-
terferes with the glycoprotein spike S, binding to its ACE2 receptor
site. However, viruses isolated from patients in a small outbreak in
2004 were all resistant to neutralization due to a single Asp/Gly
mutation. A newmAbwasmade to cover these escapemutants (Sui
et al., 2008). However, recent work has shown that even two mAbs
in combination do not prevent the emergence of escape mutants
(Sui et al., 2014).
MERS-CoV emerged in the Arabian Peninsula in 2012, but ap-
pears to have been endemic for more than 20 years. Many camels
are infected, including elite racing camels, although the primary
host may be bats. To June 2015, there had been 1150 cases with 434
deaths. Using an ScFv phage library, 7 mAbs, encompassing three
different epitopes of the S1 spike, were identified, all inhibiting
binding to the DPPD4 receptor in an SPR assay. Escape mutants
identified changes in five amino acids critical for neutralization
escape. Loss of binding to one epitope did not have a major impact
on binding of Abs directed to other epitopes, but mutants had
reduced fitness, resulting in decreased virus amplification and
reduced inflammation in the lungs of infected rhesus monkeys
(Tang et al., 2014).
Screening for antibodies against influenza A(H5N1) identified
10 mAbs which bound a common epitope on the HA stem, pre-
venting the post-attachment fusion process (Sui et al., 2009). All
appeared to use the IGHV1-69 variable heavy chain region, with
high conservation of CDR-2. These antibodies protected mice and
decreased the virus load. The antibodies cross-reacted with other
subgroup 1 influenza HAs, but not with subgroup 2. While gener-
ation of escape mutants was difficult, those selected had decreased
fitness; mutations were outside the epitope, causing destabilization
of the trimer. Another mAb, I14, was broadly active against both
groups 1 and 2, stabilizing the pre-fusion form of the HA, as
assessed by blocking trypsin cleavage of the HA0 to HA1 and HA2.
Unexpectedly, despite being selected against a group 1H5N1 strain,
its efficacy in vitro and in vivo is higher against group 2 viruses.
7.2. New antibody-based strategies against viral respiratory
diseases
Qing Zhu, Medimmune, Gaithersburg, USA.
The humanised mAb Synagis (palivizumab), which is still the
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only mAb against a viral disease approved for clinical use by the US
FDA, has been widely used for prevention of RSV infections in ne-
onates and immunocompromised individuals. RespiGam® is a hu-
man polyclonal antibody preparation also used for prevention of
RSV, but there is significant batch variation. A new mAb, MEDI8897,
which has 100-fold higher potency and neutralizes both RSV A and B
strains, has an EC90 in the cotton ratmodel of 6.5 mg/ml, compared to
57 mg/ml for palivizumab. The half life was ~40 days in monkeys and
~80 days in a Phase 1a trial in adult humans. The aim is to increase
the half life to enable a single intramuscular injection to be effective
for the whole season, thus providing vaccine-like immunity.
Another mAb, MEDI8852, neutralizes all influenza A strains by
binding a highly conserved epitope in the HA stalk, with a median
IC50 of 0.76 mg/ml. It has multiple effects on virus-induced mem-
brane fusion, HAmaturation and cellecell spread. It is claimed to be
superior to oseltamivir when given late in infection in mice and
ferrets. Given 3 days post-infection in mice there was 100% pro-
tection, versus 40% protection by oseltamivir. A combination of
MEDI8852 and oseltamivir at a suboptimal dose demonstrated a
synergistic effect. The aim is to generate a bispecific antibody
against both influenza A and B.
7.3. VIS410 monoclonal antibody demonstrates potent efficacy
against neuraminidase inhibitors-susceptible and eresistant
influenza A(H7N9) viruses and protects mice from ARDS
Tatiana Baranovich, St Jude Children's Research Hospital,
Memphis, USA.
VIS410 is a broadly neutralizing human IgG1 anti-HA antibody,
which reacts with a region of the HA stalk conserved in group 1 and
2 influenza viruses (Tharakaraman et al., 2015). It appears to have
lower affinity to H7 HA, hence its efficacy was tested against the
oseltamivir-susceptible A/Anhui/1/2013 or -resistant A/Shanghai/1/
2013 (R292K-NA) H7N9 influenza viruses in mice. VIS410 was
administered via intraperitoneal injection of either a single 50 mg/
kg dose 12 h before (prophylaxis), or a 2, 10, or 50 mg/kg dose 24 h
after (treatment) H7N9 virus inoculation. Weight loss, morbidity
and virus lung titers were monitored: Prophylactic administration
of the antibody resulted in 100% protection of the mice; a single IP
administration of 50 mg/kg 24 h post infection also provided 100%
survival, whereas the 10 mg/kg dose protected 70% of the Anhui-
infected and 90% of the Shanghai-infected mice. All doses of
VIS410 tested protectedmice fromH7N9-induced acute respiratory
distress syndrome (ARDS). There was a dose response in the
numbers of cells positive for NP. Mice developed an anti-HA im-
mune response, sufficient to provide protection against a 25 MLD50
challenge with the homologous virus.
8. Antibody-dependent enhancement (ADE) of disease:
implications for therapeutic monoclonal antibody
development
8.1. Influence of antibodies and T cells on dengue disease outcome
Sujan Shresta, La Jolla Institute for Allergy and Immunology, La
Jolla, USA.
The four types of Dengue virus (DENV) cause up to 100 million
cases, with 2.1 million severe cases and up to 21,000 deaths per
year. Infections range from asymptomatic to a self-limited febrile
illness, dengue fever (DF), to life threatening dengue hemorrhagic
fever (DHF) and dengue shock syndrome (DSS). The roles of anti-
bodies and T cells in mediating protection versus pathogenesis
remains unclear. Antibody-dependent enhancement (ADE) was
identified more than 40 years ago, and is hypothesised to be due to
the presence of subneutralizing levels of antibody and the
consequent binding of antibody-coated virus to the Fc receptors
(FcR) which facilitates virus entry, leading to enhanced infection. In
the case of secondary infections and of maternal antibody in
newborns, there may be some cross-reactive antibodies, but
insufficient to neutralize virus. Amodel of DHF/DSS-like disease has
been developed in AG129 mice lacking the type I IFN receptor
(IFNAR) and the IFN-gR (IFNAR/; IFN-gR/). This mousemodel
reproduces key pathophysiological features of DHF/DSS, including
similar cellular and tissue tropism, lethal vascular leakage, cytokine
storm, low platelet count, elevated hematocrit, and hemorrhage
(Tang et al., 2015). In order to test the hypothesis, mice were pre-
treated with different levels of antibody IP, followed by DENV
challenge: 0.5 mg of antibody was too low to have any effect; sub-
neutralizing doses of 2e15 mg led to severe disease and death;
while a fully neutralizing dose of 500 mg protected all mice. Virus
load was significantly higher at 48 h in the liver of ADE mice
compared with non-ADE mice. The importance of the interaction
between the Fc in the DENV-Ab complex and Fcg receptor was
confirmed using an antibody with a mutant Fc region that cannot
bind Fcg receptors, or Fcg receptor-blocking antibody or the Fab
fragment of anti-DENV Ab. These interventions could decrease the
enhanced virus titer in the livers of ADE mice to non-ADE levels. In
another model using a VEE replicon and the DENV E2 protein (virus
replicon particles), AG129 immunised mice had a higher survival
rate and lower virus titers when challenged with DENV (Zellweger
et al., 2013). However, passive transfer of 50e1500 ml of immune
sera resulted in ADE in recipient mice.
To determine the role of T cells, CD4 or CD8 depletion was used
to show that whereas CD4-depleted mice had low virus titers, CD8
depleted mice had high virus titers. Thus CD8 T cells conferred
greater protection. When mice were primed with UV-irradiated
dengue virus, CD8 T cells protected against ADE. Thus in terms of
vaccine development, both cellular and humoral immune re-
sponses need to be induced, and the FceFcR interaction controlled.
8.2. Influenza vaccine-induced anti-HA2 antibodies promote virus
entry and enhance lung pathology after influenza A infection
Surender Khurana, FDA, Bethesda, USA.
During the 2009 influenza A(H1N1) pandemic, several reports
suggested prior vaccination with the 2008e2009 seasonal inacti-
vated influenza vaccine increased severity of clinical disease
following infection with the A(H1N1)pdm09 virus (Skowronski
et al., 2010). The mechanism of vaccine-associated enhanced res-
piratory disease (VAERD) is not well understood. Using a swine
model, Khurana et al. (2013) showed that vaccination of pigs with
an H1N2 virus and challenge with a A(H1N1)pdm09 virus resulted
in the pigs having enhanced pneumonia and disease. Using re-
combinant expression of HA1 andHA2 and SPR binding assays, they
showed that the H1N2 sera reacted with the A(H1N1)pdm09 virus,
but that antibodies bound only to the HA2 of the H1N1 virus, and
competed with other stem-targeting antibodies. The H1N2 sera
also enhanced A(H1N1)pdm09 infection of MDCK cells and pro-
moted virus fusion activity. Only adsorption of the sera with HA2
had any effect in reducing the enhancement effect. Live vaccination
of pigs caused no ADE; however administration of the same, but
UV-inactivated, vaccine resulted in ADE. The findings of these
studies have generated concerns that clinical trials evaluating
universal vaccines and monoclonal antibody therapeutics should
monitor for antibody-associated enhanced disease.
8.3. Does antibody-dependent enhancement of disease occur in
influenza infections?
Man-Wah Tan, Genentech, San Francisco, USA.
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MHAA4549A is a human monoclonal IgG1 antibody that binds
to a highly conserved region of the HA stalk of all influenza A vi-
ruses. In a trial with an A/Wisconsin/67/2005 (H3N2) challenge, 3
intravenous doses were tested, 400, 1200 and 3600 mg
(NCT01980966). The primary end point was a decrease in virus
load, with the secondary endpoint a decrease in clinical symptoms.
The 3600 mg dose was the only one to decrease virus load. There
was no evidence of ADE, with no increase in disease severity with
the lower doses.
8.4. VIS410, a broadly neutralizing antibody to influenza A:
characterisation and potential for ADE
Jose Trevejo, Visterra Inc, Cambridge, USA.
To investigate concerns about ADE with suboptimal antibody
concentrations, infected cells were treated with low, medium and
high concentrations of the mAb VIS410. No enhancement of
infection was seen at any concentration. VIS410 was further eval-
uated in a murine macrophage cell line. Treatment with NA
removes the sialic acid receptors, resulting in decreased infection
by influenza. Addition of VIS410 increased infection through
FceFcR binding; there was no enhancement of infectivity without
NA treatment. To date resistance has been seen only in group 2
influenza viruses, with all mutations abrogating VIS410 binding,
but resulting in decreased virus fitness.
9. Host cell targets: factors involved in virus replication or
mediating the inflammatory response
9.1. Using genetic approaches to discover hostevirus interactions
Abe Brass, Ragan Institute of Massachusetts General Hospital,
USA.
To elucidate the role of host proteins in rhinovirus replication,
three sets of commercial RNAi pools were used with the readouts
based on the numbers of cells infected. The redundancy of the sets
helps address false positives and negatives. Those with more than
50% inhibition were further screened for gene expression based on
microarray. The host cell transmembrane protein RNASEK was
identified as necessary for replication of multiple HRV serotypes,
and of influenza and dengue viruses (Perreira et al., 2015). RNASEK,
in association with V-ATPase, is required for endosomal acidifica-
tion and endocytosis.
9.2. Sphingosine-1-phosphate receptor modulation of cytokine
amplification
Sean Studer, The Scripps Research Institute, La Jolla, USA.
Sphingosine 1-phosphate (S1P) is a pleiotropic lysophospholi-
pid mediator present in plasma and is released in large amounts
from activated platelets. There are 5 types of S1P receptor, S1PR1-5.
S1PR1-3 are found on various types of cells and tissues, while S1PR
4 is found mostly in cells of the immune system, and S1PR5 mostly
in the nervous system. The sphingosine analogue, AAL-R, targets
types 1, 3, 4, and 5 S1PRs, blunting the Type 1 IFN response and
cytokine induction upon influenza infection of mice, without
affecting the antibody response (Marsolais et al., 2009;Walsh et al.,
2011). In the presence of AAL-R, purified dendritic cells (DC) from
spleen and lung produced lower levels of IFN-a after virus infection
or stimulation with the IFN inducer CpG. There was also a marked
reduction in infiltration of PML and macrophages into the lung and
resultant pulmonary tissue injury. DC maturation was suppressed,
limiting proliferation of specific antiviral T cells in the lung and
draining lymph nodes. The S1P1-specific receptor agonist,
CYM5442, caused similar effects to the broadly-active AAL-R
(Walsh et al., 2011); however, S1P1 knockout is lethal in mice.
9.3. Host cell factors in influenza A virus uncoating
Ari Helenius, ETH Zurich, Switzerland.
After endocytosis, uncoating of the influenza A virus core occurs
following a two-step priming process, involving the influx of pro-
tons and Kþ ions through the M2 ion channel protein, which in-
duces irreversible conformational changes in the M1 protein,
weakening M1-vRNP association (Stauffer et al., 2014). After HA-
mediated membrane fusion the cores detach from the endosome
surface and M1 and the vRNPs dissociate from each other in the
cytosol, allowing the vRNPs to be transported through nuclear
pores into the nucleus. Treatment of cells with Importazole, an
importin inhibitor, or mutation of a consensus sequence in M1
through which transportin binds, inhibits post-fusion transport of
the vRNPs. Using siRNA silencing of cellular targets 177 hits were
obtained, with 29 affecting uncoating, and 24 nuclear import.
Knockdown of histone deacetylase 6 (HDAC6), an essential
component in ubiquitin-dependent aggresome formation and as-
sembly, reduced uncoating (Banerjee et al., 2014). HDAC6 binds to
free ubiquitin in the cytosol, via its C-terminal zinc-finger ubiq-
uitin-binding domain (UBD), and is recruited to the late endosome
surface after infection. The capsids mimic misfolded protein ag-
gregates binding the unanchored ubiquitin. Free ubiquitin is also
found in virus particles. HDAC6 associates with actin andmyosin 10
on microtubules, leading to physical disruption of the endosome/
core structure. Cleavage of the UBD by Caspase 3, prevents virus
uncoating. Thus these cellular proteins offer potential targets for
antiviral strategies.
9.4. Update on DAS181
Ronald Moss, Ansun Biopharma, USA.
DAS181 is a recombinant sialidase in which a catalytic domain,
from Actinomyces viscosus, is linked to an amphiregulin glycos-
aminoglycan respiratory epitheliumeanchoring domain, which
improves cell targeting and increases its half-life. Administered via
inhalation or a nebuliser, the sialidase cleaves terminal sialic acid
residues from glycans on the surface of respiratory cells, thus
reducing the receptors available for binding of viruses, such as
influenza and parainfluenza. In H5N1-infected mice DAS181
administered at 1 mg/kg/day from 24 h pre-to 72 h post-infection
reduced lethality (Belser et al., 2007). For mice infected with
either oseltamivir-sensitive or -resistant H7N9 viruses, 0.3, 0.6 and
1mg/kg all protected against death (Marjuki et al., 2014). In a phase
IIb trial, patients with influenza received 10 mg daily for 3 days
(multidose), or 10mg as a single dose, or placebo (Moss et al., 2012).
While both groups treated with DAS181 showed a significant
decrease in virus load at 24 h, only the multidose group showed a
significant decrease at 3 and 5 days. There was, however, no dif-
ference in the time to alleviation of clinical symptoms. More than
80 patients, primarily immunocompromised transplant patients,
have been treatedwith DAS181 on a compassionate use basis. There
was a decrease in virus load and less need for oxygenation in four
PIV-infected children (Waghmare et al., 2015). A cystic fibrosis
patient infected with an oseltamivir-resistant influenza virus
showed improvement (Silveira et al., 2015), and hematopoietic cell
transplant (HTC) recipients infected with PIV have also appeared to
benefit (Chalkias et al., 2014). Unpublished results have shown that
up to 14 of 16 patients had decreased virus load and increased
survival. A phase II trial for PIV pneumonia in immunocompro-
mised patients is currently underway. While DAS181 generally
appears safe, some patients have shown elevated alkaline phos-
phatase levels, with transient increases in liver enzymes (Moss
J.L. McKimm-Breschkin, A.M. Fry / Antiviral Research 129 (2016) 21e38 31
et al., 2012). It has systemic immunogenicity, with anti-DAS181
antibodies induced in healthy patients (Zenilman et al., 2015).
Hence, it is unlikely to be useful systemically, and it is also under-
going particle size testing to minimise systemic absorption.
9.5. A novel class of host-directed antivirals with broad spectrum
activity against respiratory viruses
Kristen Bedard, Kineta Inc, Seattle, USA.
A novel class of small molecule isoflavones has been identified,
that trigger a natural immune response by targeting the innate
immune transcription factor, IRF-3, a critical first responder
essential for suppressing virus replication and clearing infection.
Compounds were selected that cause phosphorylation of IRF-3 and
induce its nuclear translocation (Bedard et al., 2012). KIN269
enhanced interferon-stimulated gene 54 induction. SAR led to the
production of more than 250 analogues, with improvement in
EC50s from 8500 to 25 nM. Lead compounds for influenza A and B
caused more than a 3 log10 reduction in virus titers in vitro. Simi-
larly the lead compound against RSV A2 reduced virus titers by
more than 3 log10. In time of addition studies in vitro, treatment up
to 24 h post-infection reduced virus yields. These inhibitors also act
synergistically with protease inhibitors against HCV. In influenza
PR8einfected mice, treatment from 24 pre-to 24 h post-infection
with 10 mg/kg decreased lung virus titers by 2e3 log10 to 1 log10,
respectively. Pretreatment at 24 h resulted in 50% survival at 7 days,
compared to 100% lethality in the controls. While these compounds
are orally available, intranasal delivery is superior. The minimum
toxic dose is greater than 400 mg/kg, with no pathology or off-
target receptor activation, and they have no genotoxic or car-
diotoxic potential.
9.6. Potent anti-influenza and anti-inflammatory activity of
Verdinexor, a selective inhibitor of nuclear export (SINE) across a
broad panel of influenza strains, including avian influenza A H7N9
Margaret Lee, Karyopharm Therapeutics Inc, Newton, USA.
Verdinexor (KPT335) targets the nuclear export of influenza
vRNP in infected cells mediated by exportin 1 (XPO1), which in-
teracts with viral nuclear export protein bound to vRNP. Silencing of
XPO1 results in reduced influenza virus replication (Perwitasari
et al., 2014). Verdinexor binds reversibly to cysteine 528 in the
XPO1 binding pocket, inhibiting vRNP export and the replication
in vitro of various influenza A subtypes, including A(H1N1)pdm09
(IC50 200 nM), A(H3N2) (IC50 20 nM), avian A(H7N9) (IC50 420 nM)
and highly pathogenic avian A(H5N1) (IC50 270 nM), and influenza
B (IC50 10e90 nM). Treatment from 24 h pre-to 24 h post-infection
resulted in 1e2 log10 reductions in virus titer. In mice infected with
A(H1N1)pdm09, prophylaxis with 10e20 mg Verdinexor, 1e3 days
prior to infection, reduced lung virus titers. Delayed dosing at 24
and/or 72 h post-infection reduced both lung virus titers and lung
pathology. Verdinexor treatment also lowered the expression of
proinflammatory cytokines associated with influenza virus infec-
tion (g IFN, TNFa, IL-1b and IL-6). In ferrets, treatment from 2 h
post-infection for 3 days resulted in approximately a 3 log10
reduction in virus load, with minimal toxicity. Phase 1 trials of
Verdinexor are planned.
9.7. Targeting sirtuins, novel viral restriction factors, to limit
acquired resistance
Lillian Chiang, FORGE Life Science, Doylestown, USA.
Sirtuins are a family of seven NADþ- dependent deacylases
known to regulate numerous cellular functions, including meta-
bolism, the cell cycle, and longevity. They act as virus restriction
factors, since siRNA knock-down of each sirtuin increased virus
growth (Koyuncu et al., 2014). Small molecule activators of sirtuins
block in vitro replication of viruses, including influenza, HCMV,
adenovirus, and polyomavirus. Antivirals are being developed
based on Sirt1 and 2 dual inhibition, and Sirt 6 activation. The most
potent inhibitor has an IC50 of 0.4 nM. The simultaneous inhibition
of Sirt1 and 2 unexpectedly resulted in a 5-fold decrease in influ-
enza virus titer. It appears that the initial NS1 down regulation of
p53 (Terrier et al., 2013) is restored with Sirt1/2 inhibition. This
results in reactivation of p53, thus inducing apoptosis, specifically
in virus-infected cells. Compared to oseltamivir, novel Sirt1/2 in-
hibitors lead to enhanced virus clearance. Sirt/1/2 inhibitors are
already in clinical trials for Huntington's Disease, and they could act
synergistically with antivirals like oseltamivir.
9.8. Repurposing of signal transduction inhibitors to fight the flu e
an update
Stephan Ludwig, University of Muenster, Germany.
Penetration of cells by influenza viruses is controlled by various
cell signalling pathways. These include the receptor tyrosine ki-
nases, such as PI3K involved in entry/endocytosis, IKK/NFkB and
Raf/MEK/ERK involved in RNP export. Several anti-MEK inhibitors,
now in clinical trials for cancer therapy, have been investigated for
potential antiviral action against influenza. U0126 blocks nuclear
export, leading to accumulation of RNPs in the nucleus of influenza-
infected cells, and has been shown to cause an 80% decrease in lung
virus titers in influenza-infected mice, and 70% survival against
lethal infection (Droebner et al., 2011). Other MEK inhibitors have
been shown to act synergistically with oseltamivir at suboptimal
doses (Haasbach et al., 2013). The Raf inhibitor, Zelboraf (vemur-
afenib, PLX-4032), has shown greater efficacy than oseltamivir
against A(H1N1)pdm09 infection. Currently, LASAG (lysine acetyl
salicylate glycine) a derivative of aspirin, is the first molecule tar-
geting a host intracellular protein (NF-kB) to undergo a phase II
clinical trial for the treatment of severe influenza virus infection
(Ludwig et al., 2014).
9.9. Eritoran (E5564), a TLR4 antagonist effective against influenza
induced disease
Jorge Blanco, Sigmovir Biosystems, Rockville, USA.
Toll-like receptor 4 (TLR4) signalling can lead to lung inflam-
mation in influenza-infected mice and TLR4/ mice are highly
refractory to influenza induced lethality. Administration of a TLR4-
specific IgG also protected wild-type mice infected with a lethal
dose of influenza PR8. Intravenous administration of 200 mg/day of
Eritoran (E5564), a synthetic TLR4 antagonist, at 2, 4 or 6 days post-
infection, increased survival of PR8-infected mice (Shirey et al.,
2013). The mice showed reduced lung pathology, clinical symp-
toms and cytokine gene expression. Treatment with tenfold less
Eritoran decreased survival from 90% to 40% and Eritoran efficacy
decreased with increasing virus challenge, from 90% survival with
7500 TCID50 to 60% and 25% survival with 10,000 and 20,000
TCID50, respectively. Mice subsequently challenged with PR8 all
survived, indicating an immune response had developed despite
the Eritoran treatment. Cotton rats infected with non-adapted
H3N2 (A/Wuhan/359/95) and A(H1N1)pdm09 (A/California/07/
1009) influenza viruses and treated with Eritoran showed reduced
lung pathology and lower levels of IL-6 and IL-10 (Shirey et al.,
2013). In both the mice (lung homogenates) and the cotton rats
(blood), Eritoran treatment of influenza infection showed strong
reduction in concentrations of high mobility group protein 1
(HMGB1), a TLR4 agonist known to be involved in systemic
inflammation.
J.L. McKimm-Breschkin, A.M. Fry / Antiviral Research 129 (2016) 21e3832
10. Diagnostics and resistance
10.1. Detection of drug resistance in influenza: current status and
future directions
Larisa Gubareva, Centers for Disease Control and Prevention,
Atlanta, USA.
Detection of drug resistance requires knowledge of the molec-
ular mechanisms underlying the resistance phenotype, themarkers
of resistance, and criteria to correlate laboratory results with clin-
ically relevant resistance. For theM2 inhibitors, a limited number of
mutations are known to correlate with resistance in cell culture and
in vivo. However for the NAIs, cell culture sensitivity does not al-
ways correlate with reduced inhibition of the NA enzyme. Hence
enzyme-based assays have been used as a surrogate assay for
monitoring influenza virus susceptibility to NAIs. The WHO Expert
Working Group for Surveillance on Influenza Antiviral Suscepti-
bility has used the fold increase in IC50 compared with the refer-
ence IC50 value as an indicator of possible resistance. ‘Reduced
inhibition’ defines influenza A viruses with a 10- to 100-fold in-
crease in IC50, or influenza B viruses with a 5- to 50-fold increase in
IC50, and ‘highly reduced inhibition’ defines influenza A viruses
with >100-fold increase in IC50 or influenza B viruses with >50-fold
increase in IC50 (WHO, 2012). While commercial kits do not include
reference viruses, panels of resistant viruses are available from both
the CDC and isirv AVG. A major limitation of the enzyme-based
assay is that viruses must be amplified in culture for testing,
whichmay result in selection for or against resistant viruses, as well
as de novo mutations. A new bioluminescent assay may, however,
allow direct assessment of NA enzyme inhibition in clinical sam-
ples. Various sequencing methods have been used to identify NA
substitutions, including high throughput 96 well pyrosequencing
or next generation sequencing. However, while sensitive, most of
these methods only allow screening for known resistance muta-
tions. Novel mutations require the use of phenotypic assays.
Correlating the presence of low levels of resistant virus to wild type
virus in a clinical sample with lack of clinical effectiveness is also
challenging.
10.2. Characterisation of a large cluster of influenza A(H1N1)
pdm09 virus cross-resistant to oseltamivir and peramivir during the
2013e2014 influenza season
Emi Takashita, National Institute of Infectious Diseases, Tokyo,
Japan.
During the 2013e2014 influenza season, 2531 influenza
A(H1N1)pdm09 viruses from Japan were screened for the H275Y
substitution in their NA protein, which confers cross-resistance to
oseltamivir and peramivir. Prior to the main influenza season, 28%
of isolates in Sapporo/Hokkaido had the H275Y mutation
(Takashita et al., 2015). Phylogenetic analysis suggested the clonal
expansion of a single mutant virus. The virus replicated as well as
the wild type virus in cell culture and in ferrets, and was trans-
mitted as efficiently by droplet infection. H275Y-containing viruses
had two additional substitutions in NA, V241I and N369K, known to
increase replication and transmission fitness. However, modelling
suggested a third substitution (N386K) in the NA destabilised the
mutant NA structure, thus allowing the fitter wild type to compete
as the dominant strain.
10.3. Six years of monitoring emergent oseltamivir resistance in
patients with influenza A virus infections in the Influenza Resistance
Information Study (IRIS)
Bruno Lina, University Claude Bernard, Lyon, France.
Following naturally-occurring oseltamivir resistance in 2008, a
global observational study, the Influenza Resistance Information
Study (IRIS; NCT00884117) was initiated to study the emergence of
NAI resistance and the clinical course of influenza in non-
immunocompromised treated and untreated patients (Whitley
et al., 2013). Years 1e5 of the study included non-
immunocompromised patients >1 year old; year 6 included only
children aged <12 years. Of 3385 RT-PCR-positive patients infected
with a single influenza strain in years 1e6, 2468 had influenza A of
whom 1358 received oseltamivir monotherapy within 48 h of
symptom onset (9 seasonal H1N1; 734H3N2; 615 A(H1N1)pdm09).
After 2008 no baseline resistance was detected. Emergence of
resistance during or after treatment was detected in 50 oseltamivir-
treated influenza A patients (3.7% of total), mostly with a mixed
genotype (44e86% resistant). Most of these isolates were from
children 1e5 years old (22/157H1N1 and 10/174H3N2). Resistance
did not increase over the study period, within the range 3e5%. All
resistant viruses detected had either the H275Y substitution for N1
viruses (36), or the R292K substitution for N2 viruses (16). At day
10, 15/50 patients (30%) were still RT-PCR positive, although their
symptoms resolved by day 6.
10.4. The changing landscape of influenza diagnostics and the effect
on clinical management
Alicia Fry, Centers for Disease Control and Prevention, Atlanta,
USA.
Several US guidance documents recommend influenza testing,
during the influenza season, if treatment will be changed by the
test result, including outpatients at high risk for influenza com-
plications and hospitalised patients with acute respiratory illness.
Similarly, antiviral treatment is recommended for hospitalised pa-
tients and outpatients at high risk for influenza complications, with
suspected or confirmed influenza; providers are urged not to wait
for laboratory confirmation and not to rely on results of insensitive
assays before beginning treatment. However, several studies sug-
gest that insensitive rapid influenza diagnostic assays (RIDT) are
commonly used in outpatient and inpatient settings and that pro-
viders wait for the RIDT result to begin treatment. Many new
sensitive molecular diagnostic assays are now commercially avail-
able. However, while very sensitive, these assays are expensive and
several studies suggest empiric treatment during periods of high
influenza prevalence may be more cost-effective. Additional work
is needed to optimize the use of antiviral treatment for vulnerable
populations, and the role of new diagnostic assays has yet to be
determined.
11. Regulatory issues and clinical trial endpoints
11.1. Regulatory perspectives on antiviral drug development for
influenza and endpoint considerations
Peter Miele, FDA, Silver Spring, USA.
FDA guidance for the development of drugs for the treatment
and/or prophylaxis of influenza reflects experience with previous
influenza drug development and participation with working
groups (FDA, 2011). Well controlled phase 3 efficacy trials are
necessary to support FDA approval of influenza antivirals. Other
study types, e.g. human challenge studies or trials in special pop-
ulations, can contribute to the development of the clinical trial but
not substitute for it. Efficacy trials for serious influenza in hospi-
talised patients face several challenges, including a heterogeneous
population on other medications, a current standard of care that
varies by local practices, no current product with proven efficacy
that would allow an inferiority trial, and no validated clinical
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endpoint or accepted biomarker. Efficacy endpoints have not been
standardised for all types of influenza trials; most trials warrant
examination of multiple secondary endpoints. Virologic endpoints,
e.g. virus shedding, are important secondary endpoints but not
primary endpoints. FDA encourages the development of novel ef-
ficacy endpoints for trials of the treatment of serious influenza and
conducting pilot studies of them before entering into phase 3 trials.
Such endpoints should demonstrate improvement in how the pa-
tient feels, functions or survives. Early discussions with FDA can
facilitate new drug development.
11.2. Human respiratory virus challenge models: a worthwhile
challenge
Matthew Memoli, NIAID, Bethesda, USA.
Human challenge models are tools that can help to describe the
natural history and pathogenesis of influenza viruses, including
virus replication, shedding, and immune responses. In addition,
human challenge models can inform the potential benefits of new
diagnostics, vaccines and therapeutics. A new model,
H1N1pdmMIST, was recently developed by genetically modifying
the A(H1N1)pdm09 virus (Memoli et al., 2015). Challenge studies
with H1N1pdmMIST, enrolling participants with A(H1N1)pdm09
HAI titers 1:40, demonstrated that clinical symptoms of infection
and antibody responses correlated with infective dose, and that the
number and severity of symptoms correlated with viral shedding.
Baseline HA and NA antibody titers were inversely correlated with
disease severity. This model has potential to facilitate future studies
of influenza pathogenesis, animal model validation, and evaluation
of novel vaccines and therapeutics. Future models will include
genetically modified A(H3N2) and B viruses.
11.3. The human virus challenge model-accelerating drug and
vaccine development
Anthony Gilbert, Retroscreen (hVivo), London, UK.
Retroscreen have carried out more than 40 trials in the last
15years, with 20e140 patients per trial, and more than 1970 vol-
unteers. Most trials are randomised, double blind placebo
controlled, with participants aged 18e45. Viruses tested include
RSV, HRV and influenza. Primary endpoints tend to be a decrease in
virus load, by RT-PCR or cell culture.
11.4. Design and conduct of a drug development program for
severe/complicated influenza: lessons from the IV zanamivir
experience
Amanda Peppercorn, GlaxoSmithKline, North Carolina, USA.
Challenges with conducting a phase III study to evaluate the
efficacy of intravenous (IV) zanamivir in hospitalised patients
include lack of a validated clinical endpoint, inability to have a
placebo arm (oseltamivir had to be the comparator), and inability to
use a non-inferiority design since the randomised trials for osel-
tamivir licensure were performed in outpatients. The phase III
multisite randomised double-blind study compared two doses of IV
zanamivir (300 mg and 600 mg daily) to oral oseltamivir (75 mg
twice daily) in hospitalised patients aged >16 years with confirmed
influenza and symptom onset within 5 days. Primary endpoints
included hospital discharge or signs of clinical response (afebrile
and >95% O2 saturation plus two of the following: return to base-
line oxygen needs or respiratory rate <25/min, pulse <101/min and
systolic blood pressure >91mmHg). Secondary endpoints included
mortality, time to pre-morbid functional status, length of intensive
care unit and hospital stay, and several measures of virologic
improvement. Enrolment began in January 2011 and was
completed in March 2015 and analysis is ongoing; target enrolment
was 600. Interim analysis of 445 participants demonstrated that
75% of participants had underlying medical conditions and had had
symptoms for 4 days or less at enrolment. Among 348 influenza-
positive participants, the median days to clinical response was
4.71 (range 0e35) days and time to improvement in respiratory
status was 3.1 (range 0e32) days. In addition to the clinical trial,
GlaxoSmithKline has made IV zanamivir available for compas-
sionate use. Worldwide, approximately 2300 treatment courses
have been given for compassionate use, which in some countries
has affected enrolment into the clinical trial.
11.5. Challenges in designing informative clinical trials in patients
hospitalized with influenza: the peramivir experience
Sylvia Dobo, BioCryst, Durham, USA.
In a study of IV peramivir (600 mg daily) compared to placebo,
the primary endpoint was time to clinical resolution (normalization
of temperature, pulse, respiratory rate, systolic blood pressure and
oxygen saturation). Of 405 subjects enrolled, 338 had laboratory-
confirmed influenza infection; however, 217 subjects received
oseltamivir as part of standard care and were excluded from anal-
ysis. Thus, only 121 influenza infected participants qualified for
primary efficacy analysis (43 placebo, 78 peramivir); only 28% had
positive virus titers at baseline and 45% had had symptoms for
>48 h. Also, inclusion of oseltamivir in standard carewas often used
for patients who were clinically more seriously ill. Thus, the pa-
tients included in the final analysis were less ill, and may not be
representative of severe influenza, and were admitted after the
optimal time for a NAI to be effective. The study was terminated
early as it was deemed unlikely to enrol adequate numbers. The
experience with this trial highlighted several roadblocks to con-
ducting clinical trials for new antiviral drugs in hospitalised pa-
tients. Widespread availability and use of oseltamivir obfuscates
the ability to randomly allocate to a placebo group and reasons for
hospitalization vary, so that hospitalization per se may not be an
appropriate case definition for severe disease; hospitalised patients
represent a continuum of disease. There is a lack of validated
endpoints and many variables could contribute to the resolution of
the endpoints used in the peramivir study. Conducting clinical trials
in hospitalised patients with influenza thus presents unique
research difficulties. Future studiesmight be improved if enrolment
were limited to patients with documented severe illness, such as
those with lower respiratory tract illness.
11.6. Antibody-based therapy for influenza B
Man-Wah Tan, Genentech, San Francisco, USA.
NAI enzyme assays consistently demonstrate higher IC50s for
current NAIs against influenza B viruses (Burnham et al., 2013).
While the clinical implication of this is unclear, a few observational
studies suggest slower resolution of fever for oseltamivir-treated
patients with influenza B infection compared to patients with
influenza A infection. A human monoclonal antibody against
influenza B HA was demonstrated to block membrane fusion, but
not virus attachment, and to protect mice from lethal influenza B
infection.
11.7. Supporting advanced development of novel influenza antiviral
therapeutics
Michael Wathen, BARDA, Washington, USA.
BARDA's mission is to develop and provide countermeasures
against CBRN threats, pandemic influenza and emerging infectious
diseases by product development, stockpile acquisition/building,
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manufacturing infrastructure building, and product innovation.
Drug development is expensive, lengthy, and risky. Few products
make it to the stage of human studies and fewer to phase III trials.
The BARDA antiviral program has included the development of two
NAIs (IV peramivir and inhaled long acting laninamivir), an inhaled
recombinant sialidase (Fludase, DAS181), and a broad spectrum,
host-targeted small molecule (nitazoxanide). Future funding will
shift focus to unmet medical needs, including the emergence of
antiviral resistance to current drugs, treatment of severely ill pa-
tients, drugs with a wider treatment window, and discovery and
development of broadly-neutralizing antibodies. Several funding
announcements focussing on these unmet needs have been or will
be published. In addition, BARDA has convened an interagency
working group to develop better clinical endpoints for severe
influenza and improve study design of clinical trials.
11.8. Multi-center evaluation of outpatient endpoints for RSV and
other respiratory virus antivirals
John DeVincenzo, University of Tennessee, Memphis, USA.
RSV infections are common and result in an estimated 2.8e4.3
million hospital admissions globally among children <5 years of
age (Nair et al., 2010). No effective therapeutics for RSV are
currently licensed (Simoes et al., 2015). Novel therapeutics are
being developed, and challenges related to the evaluation of new
agents against severe RSV disease were discussed. RSV-infected
children who are hospitalised are admitted later in their illness
(mean 4 days) and thus might be outside the optimal therapeutic
window for most drugs. A study that included telephone surveys of
parents suggested that parents recognised difficulty in breathing,
elevated respiratory rate and wheezing, signs of lower respiratory
illness, early in RSV infection. Approximately 56% of children were
taken for medical carewithin 1 day of illness onset and 100%within
3 days of illness onset. Thus, studies to evaluate new therapeutics
that targeted ambulatory patients may be feasible and prevention
of hospitalization could be a clinical outcome.
12. Conclusions
New anti-influenza therapeutic agents could improve morbidity
associated with influenza, especially those that target treatment of
severe influenza and with a wider therapeutic window than 48 h.
Several novel agents with the potential to add to the current
armamentarium against influenza were described. Additional
studies on other respiratory viruses were presented, including
those targeting the proteins involved in replication, receptor
binding and fusion, and host cell targets. While each is in a different
phase of development, few have made it to human studies. Future
challenges include identifying the best methods to evaluate efficacy
against severe influenza and other respiratory diseases and to
monitor for adverse effects related to antibodies.
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